Plain language summary of mortality rates in patients with Parkinson’s disease psychosis treated with pimavanserin or other atypical antipsychotics

This Plain Language Summary of Publication article (PLSP) from Future Neurology, describes a study comparing the risk of death in patients aged 65 or older with Parkinson’s disease psychosis who were treated with either pimavanserin or other off-label antipsychotics. While pimavanserin is the only FDA-approved treatment for Parkinson’s disease psychosis, other antipsychotics are sometimes used, despite an FDA warning about increased death risk in elderly dementia patients. The study found that patients taking pimavanserin had a lower risk of death compared to those using other antipsychotic medications.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study’ and was published in Drug Safety.

Visit Springer Nature Link using the link to read the original article.

• mortality
• Parkinson's disease
• pimavanserin
• psychosis